Imiquimod

Carcinoma, Non-Small-Cell Lung

UbiVacSmall moleculePhase 2Dormant

CCC

51/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 65/ 100

Competitive context

1206 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / Sponsor	Phase	Rating
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB
Onartuzumab Hoffmann-La Roche	Phase 3	BBB

View all 50 →

Same molecule, other indications

Imiquimod is also rated in:

lentigo maligna melanomaDormant

BBB

Indicative ·

77 / 100

squamous cell intraepithelial neoplasiaDormant

B

Indicative ·

63 / 100

human papilloma virus infectionDormant

B

Indicative ·

63 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.